½ÃÀ庸°í¼­
»óǰÄÚµå
1326556

¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø, ±â¿øº°, Á¦Ç° ¼­ºñ½ºº°, Áúº´ ÀûÀÀÁõº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Biologics Contract Development Market Size Study & Forecast, By Source, by Product Service, by Disease Indication and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀåÀº 2022³â ¾à 60¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ÀÎ 2023-2030³â 10.5% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

»ý¹°ÀǾàǰ À§Å¹°³¹ßÀº »ý¹°ÇÐÀû Á¦Á¦³ª Ä¡·áÁ¦ÀÇ °³¹ß ¹× Á¦Á¶ ¼­ºñ½º¸¦ °³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO) ¶Ç´Â ¿¬±¸°³¹ß¼öʱâ°ü(CRO)¿¡ À§Å¹ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ´Ü¹éÁú, Ç×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·áÁ¦ µî »ýü À¯·¡ÀÇ º¹ÀâÇÑ ºÐÀÚ¸¦ ¸»ÇÕ´Ï´Ù. »ý¹°ÇÐÀû »ý»ê¿¡ ÷´Ü ±â¼ú µµÀÔÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀÇ Ã˸ÅÁ¦·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»çÀÇ ÀǾàǰ °³¹ß ¹æ¹ý Áõ°¡, ½ÄǰÀǾ౹ÀÇ ÀǾàǰ ½ÂÀÎÀ² Áõ°¡, Ç¥Àû ¾à¸®¿ä¹ýÀÇ »ç¿ë Áõ°¡, °³ÀÎ ¸ÂÃãÇü ¾à¹°¿ä¹ý¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡ µîµµ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½Å°æÁúȯ, ºÎÀΰúÁúȯ, ¾Ï, ¾È°úÁúȯ, ½ÉÇ÷°üÁúȯ µî ÁúȯÀÇ ±ÞÁõÀº ¼¼°è ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.2022³â ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¾ÏÀº ¼¼°è ÁÖ¿ä »ç¸Á¿øÀÎ Áß Çϳª·Î 2020³â 1,000¸¸ ¸í ÀÌ»óÀÌ »ç¸ÁÇß½À´Ï´Ù. Cancer TomorrowÀÇ ¿¹Ãø¿¡ µû¸£¸é 2020³â¿¡´Â ¾à 1,930¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ º¸°íµÉ °ÍÀ̸ç, ÀÌ ¼öÄ¡´Â 2040³â±îÁö 3,020¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡¼­ ÇコÄɾî CDMO´Â ȯÀÚ Ä¡·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ¿Ö³ÄÇÏ¸é ¸¹Àº ¹ÙÀÌ¿À Á¦¾à±â¾÷µéÀÌ Áúº´ Ä¡·á¸¦ À§ÇÑ ½Å¾àÀ̳ª µ¿±Þ ÃÖ°­ÀÇ Á¦Ç°À» °³¹ßÇϰíÀÚ Çϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, »ý¹°ÇÐÀû Á¦Á¦ °³¹ßÀ» À§ÇÑ Ã·´Ü ±â¼ú äÅà Áõ°¡, ½ÅÈï±¹ÀÇ ÀÓ»ó½ÃÇè¿¡ À¯¸®ÇÑ È¯°æ, ÷´Ü »ý¹°ÇÐÀû Á¦Á¦ °³¹ßÀ» À§ÇÑ ÇöÁö ±â¾÷°úÀÇ Á¦ÈÞ, °è¾à ¹× ÇÕº´ Áõ°¡, ¹ÙÀÌ¿À Á¦¾à ºÎ¹®ÀÇ Á¦Á¶ À¯¿¬¼ºÀ» ³ôÀ̱â À§ÇÑ °³¹ß Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» À§ÇÑ ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ °øÁ¤ÀÇ ³ôÀº ºñ¿ë°ú ÀÌ·¯ÇÑ Á¦Ç°ÀÇ »ç¿ë¹ý¿¡ ´ëÇÑ ÀÌÇØ ºÎÁ·Àº »ý¹°Á¦Á¦ ¼öŹ °³¹ß »ê¾÷ÀÇ ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.

¼¼°è »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀåÀ» Á¶»çÇÏ´Â ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«°¡ ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â 2021³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü·«Àû Á¦ÈÞ ¹× Àμö, Àü¹® ½ÃÇè ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. CDO(Contract Development Organization)ÀÇ ¼ºÀåÀº ÁÖ·Î ÀÌ Áö¿ªÀÇ ÀÓ»ó½ÃÇè ¹× ¾Æ¿ô¼Ò½Ì Ȱµ¿ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ÀÌ Áö¿ªÀÇ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ ¼¼°è ¿ä±¸¿¡ µû¶ó ÀÓ»ó½ÃÇè Æò°¡ ±âÁØÀ» ¾÷µ¥ÀÌÆ®Çϱâ À§ÇØ ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ Á¶Á¤µÇ°í Àֱ⠶§¹®¿¡ »ý¸í °øÇÐ ±â¾÷µéÀº ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°è ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ¿ªÇÐ

  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ´Ù¾çÇÑ ´ë»ó Áúȯ À¯º´·ü »ó½Â
      • Á¦¾à ±â¾÷¿¡ ÀÇÇÑ ÀǾàǰ °³¹ß ¹æ¹ý Áõ°¡
      • ¼ÒºñÀÚ¿¡ ÀÇÇÑ ¸ÂÃãÇü ÀÇ·á¿¡ÀÇ ÁöÇâ Áõ°¡
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • »ý¹°Á¦Á¦ Á¦Á¶ °øÁ¤ °íºñ¿ë
    • ½ÃÀå ±âȸ
      • »ý¹°ÇÐÀû °³¹ßÀ» À§ÇÑ Ã·´Ü±â¼ú µµÀÔ Áõ°¡
      • ¹ÙÀÌ¿ÀÀǾàǰ ºÎ¹® Á¦Á¶ À¯¿¬¼º Çâ»ó

Á¦4Àå ¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå : À¯·¡º°

  • ½ÃÀå ÇöȲ
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå : À¯·¡º°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå, À¯·¡º° ÃßÁ¤¡¤¿¹Ãø : 2020-2030³â
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¹Ì»ý¹°
    • Æ÷À¯·ù
    • ±âŸ

Á¦6Àå »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå : Á¦Ç° ¼­ºñ½ºº°

  • ½ÃÀå ÇöȲ
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå : Á¦Ç° ¼­ºñ½ºº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå : Á¦Ç° ¼­ºñ½ºº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ¼¼Æ÷ÁÖ °³¹ß
    • ÇÁ·Î¼¼½º °³¹ß
    • ±âŸ

Á¦7Àå »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå, Áúȯ ÀûÀÀÁõº°

  • ½ÃÀå ÇöȲ
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå : Áúȯ ÀûÀÀÁõº°, ½ÇÀû-°¡´É¼º ºÐ¼®
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå, Áúȯ ÀûÀÀÁõº°, 2020³â-2030³â ÃßÁ¤¡¤¿¹Ãø
  • »ý¹°Á¦Á¦ °³¹ß ¼öŹ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ¾Ï¿µ¿ª
    • ¸é¿ª Áúȯ
    • ½ÉÇ÷°üÁúȯ
    • Ç÷¾× Áúȯ
    • ±âŸ

Á¦8Àå »ý¹°Á¦Á¦ ¼öŹ °³¹ß ¼¼°è ½ÃÀå, Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • À¯·¡º° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Á¦Ç° ¼­ºñ½ºº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Áúȯ ÀûÀÀÁõº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • WuXi Biologics
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Abzena Ltd
    • Fujifilm Diosynth Biotechnologies
    • KBI Biopharma, Inc.
    • AGC Biologics
    • Thermo Fisher Scientific Inc.
    • Curia Global, Inc.
    • Genscript
    • Bionova Scientific, Inc.
    • BioXcellence(Boehringer Ingelheim Biopharmaceuticals GmbH)

Á¦10Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
LSH 23.09.18

Global Biologics Contract Development Market is valued at approximately USD 6.08 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2023-2030. Biologics contract development refers to the outsourcing of development and manufacturing services for biologic drugs or therapies to contract development and manufacturing organizations (CDMOs) or contract research organizations (CROs). Biologics are complex molecules derived from living organisms, including proteins, antibodies, vaccines, and gene therapies. The rising adoption of advanced technology for biological production is acting as a catalyzing factor for market growth. Furthermore, increased drug development methods by pharmaceutical companies, increased drug approval rates by the Food and Drug Administration, increased use of targeted pharmacological therapies, and increased desire for personalized medication are some of the factors resulting in the increase in market growth.

In addition, the surging prevalence of diseases such as neurological illnesses, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders are contributing to the market development across the globe. According to World Health Organization in 2022, cancer is one of the main causes of death worldwide, accounting for over 10 million deaths in 2020. According to Cancer Tomorrow predictions in 2020, approximately 19.3 million cancer cases were reported in 2020, with this figure anticipated to climb to 30.2 million by 2040. In such circumstances, healthcare CDMOs play an important role in patient care because many biopharma companies aspire to develop novel medicines or first-in-class products for illness treatment. Furthermore, an increase in the adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries, an increase in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and an increase in the development of greater manufacturing flexibility in the biopharmaceutical sector is expected to provide lucrative opportunities for market growth over the forecasting period. However, the high cost of biologics production processes, as well as a lack of understanding about the usage of these products, limit the growth of the biologics contract development industry.

The key regions considered for the Global Biologics Contract Development Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to lead the market in 2021. Strategic collaborations and acquisitions, as well as growing demand for specialized testing services, are driving the market. The growth of contract development organizations (CDOs) can be attributed mostly to the region's increased clinical trial and outsourcing activity. Furthermore, the high prevalence of chronic diseases is substantial fostering the demand for clinical studies in this region. These factors drive market expansion. Asia Pacific is expected to be the fastest growing region during the forecast period, because of different regulatory organization adjustments to update clinical trial evaluation standards based on global needs, biotechnology businesses are investing in the Asia Pacific region.

Major market players included in this report are:

  • WuXi Biologics
  • Abzena Ltd
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma, Inc.
  • AGC Biologics
  • Thermo Fisher Scientific Inc.
  • Curia Global, Inc.
  • Genscript
  • Bionova Scientific, Inc.
  • BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Recent Developments in the Market:

  • In September 2020, Almac Group recently announced the beginning of a contract for testing and development services for biologics. The development and testing of new biologic products will benefit from this expansion.
  • In February 2020, Lake Pharma In., Inc. has announced the debut of combined chemistry and biologics services, for faster antibody-drug conjugates development solutions for the pharmaceutical and biotechnology sectors.

Global Biologics Contract Development Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Source, Product Services, Disease Indication, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Source:

  • Microbial
  • Mammalian
  • Others

By Product Service:

  • Cell Line Development
  • Process Development
  • Others

By Disease Indication:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Biologics Contract Development Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Biologics Contract Development Market, by Source, 2020-2030 (USD Billion)
    • 1.2.3. Biologics Contract Development Market, by Product Service, 2020-2030 (USD Billion)
    • 1.2.4. Biologics Contract Development Market, by Disease Indication, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Biologics Contract Development Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Biologics Contract Development Market Dynamics

  • 3.1. Biologics Contract Development Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of various target diseases
      • 3.1.1.2. Increased drug development methods by pharmaceutical companies population
      • 3.1.1.3. Increased inclination for personalised medication by consumers
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of biologics production processes
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the adoption of advanced technologies for biological development
      • 3.1.3.2. Increase in the development of greater manufacturing flexibility in the biopharmaceutical sector

Chapter 4. Global Biologics Contract Development Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Biologics Contract Development Market, by Source

  • 5.1. Market Snapshot
  • 5.2. Global Biologics Contract Development Market by Source, Performance - Potential Analysis
  • 5.3. Global Biologics Contract Development Market Estimates & Forecasts by Source 2020-2030 (USD Billion)
  • 5.4. Biologics Contract Development Market, Sub Segment Analysis
    • 5.4.1. Microbial
    • 5.4.2. Mammalian
    • 5.4.3. Others

Chapter 6. Global Biologics Contract Development Market, by Product Service

  • 6.1. Market Snapshot
  • 6.2. Global Biologics Contract Development Market by Product Service, Performance - Potential Analysis
  • 6.3. Global Biologics Contract Development Market Estimates & Forecasts by Product Service 2020-2030 (USD Billion)
  • 6.4. Biologics Contract Development Market, Sub Segment Analysis
    • 6.4.1. Cell Line Development
    • 6.4.2. Process Development
    • 6.4.3. Others

Chapter 7. Global Biologics Contract Development Market, by Disease Indication

  • 7.1. Market Snapshot
  • 7.2. Global Biologics Contract Development Market by Disease Indication, Performance - Potential Analysis
  • 7.3. Global Biologics Contract Development Market Estimates & Forecasts by Disease Indication 2020-2030 (USD Billion)
  • 7.4. Biologics Contract Development Market, Sub Segment Analysis
    • 7.4.1. Oncology
    • 7.4.2. Immunological Disorders
    • 7.4.3. Cardiovascular Disorders
    • 7.4.4. Hematological Disorders
    • 7.4.5. Others

Chapter 8. Global Biologics Contract Development Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Biologics Contract Development Market, Regional Market Snapshot
  • 8.4. North America Biologics Contract Development Market
    • 8.4.1. U.S. Biologics Contract Development Market
      • 8.4.1.1. Source breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Product Service breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Disease Indication breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Biologics Contract Development Market
  • 8.5. Europe Biologics Contract Development Market Snapshot
    • 8.5.1. U.K. Biologics Contract Development Market
    • 8.5.2. Germany Biologics Contract Development Market
    • 8.5.3. France Biologics Contract Development Market
    • 8.5.4. Spain Biologics Contract Development Market
    • 8.5.5. Italy Biologics Contract Development Market
    • 8.5.6. Rest of Europe Biologics Contract Development Market
  • 8.6. Asia-Pacific Biologics Contract Development Market Snapshot
    • 8.6.1. China Biologics Contract Development Market
    • 8.6.2. India Biologics Contract Development Market
    • 8.6.3. Japan Biologics Contract Development Market
    • 8.6.4. Australia Biologics Contract Development Market
    • 8.6.5. South Korea Biologics Contract Development Market
    • 8.6.6. Rest of Asia Pacific Biologics Contract Development Market
  • 8.7. Latin America Biologics Contract Development Market Snapshot
    • 8.7.1. Brazil Biologics Contract Development Market
    • 8.7.2. Mexico Biologics Contract Development Market
  • 8.8. Middle East & Africa Biologics Contract Development Market
    • 8.8.1. Saudi Arabia Biologics Contract Development Market
    • 8.8.2. South Africa Biologics Contract Development Market
    • 8.8.3. Rest of Middle East & Africa Biologics Contract Development Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. WuXi Biologics
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Abzena Ltd
    • 9.3.3. Fujifilm Diosynth Biotechnologies
    • 9.3.4. KBI Biopharma, Inc.
    • 9.3.5. AGC Biologics
    • 9.3.6. Thermo Fisher Scientific Inc.
    • 9.3.7. Curia Global, Inc.
    • 9.3.8. Genscript
    • 9.3.9. Bionova Scientific, Inc.
    • 9.3.10. BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦